40.02 USD
+0.18 (+0.45%)
40.02 USD
0 (0%)
Taking everything into account, RPRX scores 6 out of 10 in our fundamental rating. RPRX was compared to 192 industry peers in the Pharmaceuticals industry. RPRX scores excellent on profitability, but there are some minor concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
RPRX had positive earnings in the past year.
RPRX had a positive operating cash flow in the past year.
Each year in the past 5 years RPRX has been profitable.
RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.95%, RPRX belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
RPRX's Return On Equity of 11.93% is amongst the best of the industry. RPRX outperforms 86.98% of its industry peers.
RPRX has a Return On Invested Capital of 6.43%. This is amongst the best in the industry. RPRX outperforms 84.38% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.71%.
The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
RPRX has a Profit Margin of 32.55%. This is amongst the best in the industry. RPRX outperforms 95.83% of its industry peers.
In the last couple of years the Profit Margin of RPRX has declined.
RPRX's Operating Margin of 65.22% is amongst the best of the industry. RPRX outperforms 100.00% of its industry peers.
RPRX's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
RPRX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, RPRX has more shares outstanding
The debt/assets ratio for RPRX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.70, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.70, RPRX is in line with its industry, outperforming 58.85% of the companies in the same industry.
The Debt to FCF ratio of RPRX is 9.47, which is on the high side as it means it would take RPRX, 9.47 years of fcf income to pay off all of its debts.
RPRX's Debt to FCF ratio of 9.47 is fine compared to the rest of the industry. RPRX outperforms 78.13% of its industry peers.
A Debt/Equity ratio of 1.34 is on the high side and indicates that RPRX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.34, RPRX is doing worse than 76.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.7 |
ROIC/WACC0.78
WACC8.25%
2.3 Liquidity
RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 54.17% of the companies in the same industry.
A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
RPRX has a Quick ratio (3.48) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.24% over the past year.
Measured over the past years, RPRX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -18.23% on average per year.
RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 4.52% on average per year.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.58% yearly.
RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.36% yearly.
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RPRX is valuated reasonably with a Price/Earnings ratio of 9.74.
Based on the Price/Earnings ratio, RPRX is valued cheaper than 91.67% of the companies in the same industry.
When comparing the Price/Earnings ratio of RPRX to the average of the S&P500 Index (26.31), we can say RPRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.90, the valuation of RPRX can be described as very cheap.
91.15% of the companies in the same industry are more expensive than RPRX, based on the Price/Forward Earnings ratio.
RPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.74 | ||
| Fwd PE | 7.9 |
4.2 Price Multiples
RPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RPRX is cheaper than 82.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.45 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RPRX may justify a higher PE ratio.
PEG (NY)0.83
PEG (5Y)N/A
EPS Next 2Y11.15%
EPS Next 3Y11.71%
5. Dividend
5.1 Amount
RPRX has a Yearly Dividend Yield of 2.21%.
Compared to an average industry Dividend Yield of 6.81, RPRX pays a better dividend. On top of this RPRX pays more dividend than 93.23% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.21% |
5.2 History
RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
40.02
+0.18 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.15%
Inst Owner Change-2.77%
Ins Owners1.79%
Ins Owner Change9.31%
Market Cap23.10B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts82.67
Price Target46 (14.94%)
Short Float %3.61%
Short Ratio3.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.21% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)3.8%
PT rev (3m)4.2%
EPS NQ rev (1m)2.11%
EPS NQ rev (3m)1.92%
EPS NY rev (1m)0.13%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)4.57%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)1.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.74 | ||
| Fwd PE | 7.9 | ||
| P/S | 9.83 | ||
| P/FCF | 24.45 | ||
| P/OCF | 9.6 | ||
| P/B | 3.6 | ||
| P/tB | 4.21 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.27%
EPS(NY)5.07
Fwd EY12.66%
FCF(TTM)1.64
FCFY4.09%
OCF(TTM)4.17
OCFY10.41%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.83
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.7 |
F-Score5
WACC8.25%
ROIC/WACC0.78
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year28.89%
EBIT Next 3Y14.6%
EBIT Next 5Y13.57%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status of ROYALTY PHARMA PLC- CL A (RPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
Can you provide the profitability details for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.74 and the Price/Book (PB) ratio is 3.6.
Is the dividend of ROYALTY PHARMA PLC- CL A sustainable?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.